stillfinite

In hardware, if too much of the product has to be customized or there is too much variation, you can only win by being Oracle, charging exorbitant amounts to a small set of customers. The market in industrial IoT is not nearly so concentrated, and so the best strategy is probably to pick some lucrative subfield and expand around that. Try to make products that cover everything and you will just get killed by unit economics. But there is no gigantic, homogenous market like "all humans with a disposable income" that the iPhone got to cover, so IoT will always be somewhat competitive.

The significant thing about CAR-T cell therapy is that it's not very specific to the type of cancer - all cancer cells have damaged DNA that leads to the productions of antigens. Leukemia is the low-hanging fruit because it's easy to inject the T-cells back into the body right where the cancers cells are. It's hard to tell whether you could get enough T-cells to diffuse out of the bloodstream to have an effect on something like prostate cancer. It would be a real breakthrough if you could overcome that hurdle, because then you would have a treatment that works on many different cancers without much modification.